

Rhythm Maintains ISO Certification

Highlights

- ✓ Rhythm retains ISO certification for its Quality Management System for sixth consecutive year; and
- ✓ ISO certification key to supporting regulatory compliance, operational readiness and global commercialisation activities.

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: RHY) (**Rhythm** or the **Company**) is pleased to confirm it continues to comply with ISO certification to the International Standard for In-Vitro Diagnostics and Medical Devices (ISO 13485:2016), for Rhythm Biosciences.

ISO 13485:2016 is the internationally recognised quality standard to ensure the consistent design, development, manufacture, and sale of medical devices that are safe for their intended purposes. The ISO certification was conducted by the British Standards Institution (BSI) and marks the sixth consecutive year that Rhythm has achieved and maintained certification with the ISO standard.

ISO certification is a critical component of the Company's commercial and market entry strategies, as it supports the regulatory approval processes, confidence in the market and from partners for Rhythm's operational credibility and validates the systems the Company has established and maintained over an extended period to deliver its transformative aid to cancer diagnosis technology.

Commenting on the ISO certification, **Rhythm Quality Manager, Donald Joseph, said:**

"Rhythm continues to maintain a Quality Management System in line with ISO13485:2016, allowing us to prepare for the launch of ColoSTAT® into the relevant markets internationally."

- ENDS -

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investor@rhythmbio.com:

Mr. Otto Buttula Executive Chairman	Ms. Andrea Steele General Counsel & Joint Company Secretary
-----------------------------------------------	-----------------------------------------------------------------------

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

www.rhythmbio.com

Australian Registered Address
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

T +61 3 8256 2880
E info@rhythmbio.com

Directors

Otto Buttula
Sue MacLeman

Trevor Lockett
Louis Panaccio

Executive Chairman
Non-Executive Independent
Deputy Chair
Non-Executive Director
Non-Executive Director

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and Twitter.

About ColoSTAT[®]

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable. The ColoSTAT[®] Test-Kit is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet the IVDR (In vitro diagnostic medical devices regulation) regulatory standards.

The ColoSTAT[®] Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.